Copyright
©The Author(s) 2023.
World J Clin Cases. Nov 16, 2023; 11(32): 7814-7821
Published online Nov 16, 2023. doi: 10.12998/wjcc.v11.i32.7814
Published online Nov 16, 2023. doi: 10.12998/wjcc.v11.i32.7814
Table 2 Primary outcome and its components
| Outcome | Aspirin group (n = 30) | No aspirin group (n = 30) | Relative risk (95%CI) | P value |
| Primary outcome, n (%) | 2 (6.7) | 5 (16.7) | 0.40 (0.12-1.31) | |
| Recurrent stroke, n (%) | 1 (3.3) | 3 (10) | 0.33 (0.04-2.76) | 0.31 |
| Myocardial infarction, n (%) | 1 (3.3) | 1 (3.3) | 1.00 (0.07-14.42) | 1.00 |
| Vascular death, n (%) | 1 (3.3) | 2 (6.7) | 0.50 (0.05-4.79) | 0.55 |
- Citation: Zhang JQ, Pan ZB. Efficacy and safety of aspirin antiplatelet therapy within 48 h of symptom onset in patients with acute stroke. World J Clin Cases 2023; 11(32): 7814-7821
- URL: https://www.wjgnet.com/2307-8960/full/v11/i32/7814.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i32.7814